ELAN · Elanco Animal Health Inc
$23.67
+1.16 (+5.15%)
At close · Aug 14
Market Cap
$11.83B
Shares
499.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.67
Open$22.75
Day$22.67–23.69
52W close$17.35–26.84
Avg vol 30d7.0M
Short int36.0M · 7.2% float · 7.3d
Short vol59%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−4%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
67%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−4%
trailing
YTD return
+5%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $24 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +79 funds added
Insider flow
Accumulating
Net +$442.9K over 90 days · 0% sells
Short interest
Rising
7.21% of float · ▲ +0.5% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
512 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
55%
expanding
EPS growth
−169%
Y/Y
Free cash flow
$284.0M
Balance sheet
$3.8B
net debt
Quant / Vol
risk profile
Volatility
42%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Innovation revenue
· Full Year 2026
$1.25B
Adjusted EBITDA
· Full Year 2026
Non-GAAP
$1.01B – $1.04B
Revenue
· Full Year 2026
$5.09B – $5.14B
Adjusted EPS
· Full Year 2026
Non-GAAP
$1.10 – $1.16
Prior guidance
period ended
· from the 8-K filed Feb 24, 2026
Revenue
· 2026 First Quarter
$1.28B – $1.31B
Adjusted EBITDA
· 2026 First Quarter
$290M – $310M
Adjusted Earnings per Share
· 2026 First Quarter
$0.33 – $0.36
Guided vs delivered
· last 3 settled
Revenue
second quarter
guided $1.15B – $1.17B
$1.18B
Beat +2.3%
Revenue
full year 2024
guided $4.45B – $4.54B
$4.44B
Miss −1.2%
Revenue
first quarter 2024
guided $1.16B – $1.19B
$1.21B
Beat +2.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−4%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $25 › 200d $24 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +79 funds added
Insider flow
Accumulating
Net +$442.9K over 90 days · 0% sells
Short interest
Rising
7.21% of float · ▲ +0.5% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
512 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $24 · 67%
Range high $27
vs 200-day avg +0%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $0.75 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $622M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 22.9% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted gross margin percentage non-GAAP | 57.5% | Six Months Ended June 30, 2026 | — |
| Adjusted gross profit non-GAAP | $1.57B | Six Months Ended June 30, 2026 | — |
| Adjusted net income non-GAAP | $378M | Six Months Ended June 30, 2026 | — |
| Net leverage ratio non-GAAP | 3.1 | As of June 30, 2026 | — |
| Organic constant currency revenue growth non-GAAP | 8% | Q2 2026 | — |
|
|
|||
| Trailing twelve month adjusted EBITDA non-GAAP | $1.01B | As of June 30, 2026 | — |
| Innovation revenue | $892M | full year | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELAN
this stock
Elanco Animal Health Inc
|
$11.83B | +4.6% | +6.2% | — | 7.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELAN | +7.0% | -8.4% | -4.4% | -10.2% | +4.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +6.6% | -12.8% | -18.1% | -14.2% | -9.3% |
Key facts
CIK
1739104
CUSIP
28414H103
13F (30d)
495 filings
469 filers
Visit website
Investor relations